Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

DarioHealth Corp.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SECOND QUARTER 2025 REVENUE WAS $5.4 MILLION, COMPARED TO $6.3 MILLION IN THE SECOND QUARTER OF 2024, AND $6.8 MILLION IN THE FIRST QUARTER OF 2025 - THE COMPANY BELIEVES THAT STRONG CLIENT MOMENTUM AND STRATEGIC WINS WILL OFFSET DECREASE IN REVENUES APPROXIMATELY $5 MILLION NEW COMMITTED ANNUAL RECURRING REVENUES ("CARR"); PLUS $53 MILLION PIPELINE OF COMMERCIAL OPPORTUNITIES, OVER $5 MILLION OF WHICH IS IN FINAL STAGES TOWARD CARR - ON TRACK TO SECURE TOTAL OF 40 NEW CLIENTS BY THE END OF 2025 TWO NEW HEALTH PLAN CLIENTS ARE EXPECTED TO REPRESENT MULTI-MILLION-DOLLAR OPPORTUNITIES FOR DARIO OVER TIME, INCLUDING A FULL-SUITE NATIONAL HEALTH PLAN SCHEDULED TO LAUNCH IN THE SECOND HALF OF 2025 GROSS MARGIN INCREASED TO 55% COMPARED TO 44% IN THE SECOND QUARTER OF 2024 THE CORE BUSINESS-TO-BUSINESS-TO-CONSUMER ("B2B2C") HAS BEEN OPERATING AT APPROXIMATELY 80% GROSS MARGINS ON A NON-GAAP BASIS SINCE THE FIRST QUARTER OF 2024 OPERATING LOSS IN THE SECOND QUARTER OF 2025 NARROWED BY 43% COMPARED TO THE SECOND QUARTER OF 2024 OPERATING EXPENSES FOR THE SECOND QUARTER OF 2025 DECREASED BY $6.8 MILLION, OR 36%, FROM THE SECOND QUARTER OF 2024 WITH ADDITIONAL EFFICIENCIES ANTICIPATED THROUGH ONGOING AI-DRIVEN PROCESS OPTIMIZATION DARIO WILL HOST AN INVESTOR CONFERENCE CALL AND WEBCAST AT 8:30 A.M. ET TODAY NEW YORK , AUG. 12, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, ALONG WITH STRATEGIC AND COMMERCIAL UPDATES.

DARIOHEALTH REPORTS SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS

COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:30 A.M. EASTERN TIME NEW YORK , AUG. 5, 2025 /PRNEWSWIRE/ --DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, ANNOUNCED TODAY THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE 2ND QUARTER ENDED JUNE 30 TH, 2025 AND WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30 A.M.

DARIOHEALTH TO REPORT SECOND QUARTER 2025 RESULTS ON TUESDAY, AUGUST 12, 2025

DARIO AND GREENKEY JOIN FORCES TO TARGET $150 BILLION SLEEP APNEA MARKET, ADDRESSING 29 MILLION AMERICANS WITH UNMET NEEDS THROUGH INTEGRATED CHRONIC CARE SOLUTION NEW YORK AND SAN FRANCISCO , JUNE 26, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ('DARIO' OR THE 'COMPANY'), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED A STRATEGIC COMMERCIAL AGREEMENT WITH GREENKEY HEALTH ('GREENKEY'), AN INNOVATOR IN VALUE-BASED SLEEP HEALTH SOLUTIONS, TO BRING THE COMPREHENSIVE CARE PROGRAM TO PAYERS NATIONWIDE. THE COLLABORATION LEVERAGES THE STRENGTHS OF BOTH COMPANIES TO DELIVER A TIERED, DATA-DRIVEN SOLUTION FOR IMPROVING MEMBER HEALTH OUTCOMES, REDUCING HEALTHCARE COSTS, AND ENHANCING PRODUCTIVITY THROUGH THE INTEGRATION OF BEHAVIORAL HEALTH, SLEEP, AND CARDIOMETABOLIC CARE.

DARIO AND GREENKEY HEALTH ANNOUNCE STRATEGIC COMMERCIAL AGREEMENT TO TRANSFORM CHRONIC CONDITION MANAGEMENT AND SLEEP HEALTH FOR PAYERS NATIONWIDE

DARIO'S NEW RESEARCH SHOWS SUSTAINED OUTCOMES POST-GLP-1 FOR PLATFORM USERS AND 89% ACCURACY IN INNOVATIVE AI BLOOD GLUCOSE PREDICTION; THE COMPANY IS ACTIVELY WORKING TO LEVERAGE THESE FINDINGS IN COMMERCIAL DISCUSSIONS NEW YORK , JUNE 24, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED FOUR NEW STUDIES PRESENTED THIS PAST WEEKEND AT THE 85TH ANNUAL AMERICAN DIABETES ASSOCIATION ("ADA") SCIENTIFIC SESSIONS IN CHICAGO. THE RESEARCH, WHICH REPRESENTS DARIO'S 25TH PUBLISHED STUDY AT THE ADA'S SCIENTIFIC SESSIONS OVER THE LAST DECADE, INCLUDES GROUNDBREAKING FINDINGS IN SUSTAINING GLP-1 WEIGHT LOSS AND ARTIFICIAL INTELLIGENCE ("AI")-POWERED PERSONALIZATION THAT HIGHLIGHT THE COMPANY'S PLATFORM'S CRITICAL CONTRIBUTION IN THE DIGITAL HEALTH MARKET.

DARIO UNVEILS GROUNDBREAKING GLP-1 AND AI-PERSONALIZATION DIGITAL HEALTH FINDINGS

FIRST QUARTER REVENUE OF $6.75 MILLION, A 17% INCREASE YEAR-OVER-YEAR, DRIVEN BY EMPLOYER AND HEALTH PLAN (B2B2C) GROWTH, AND A DECREASE OF 11% SEQUENTIALLY. GROSS MARGIN INCREASED TO 57.5% COMPARED TO 42.2% IN THE FIRST QUARTER OF 2024 GROSS MARGIN (NON-GAAP) INCREASED TO 70.5%, UP FROM 62.4% IN THE FIRST QUARTER OF 2024 OPERATING EXPENSES DECREASED BY 35% COMPARED TO THE FIRST QUARTER OF 2024 AND 16% SEQUENTIALLY, WITH ADDITIONAL EFFICIENCIES ANTICIPATED THROUGH ONGOING AI-DRIVEN PROCESS OPTIMIZATION GAAP OPERATING LOSS DECREASED BY 47% COMPARED TO THE FIRST QUARTER OF 2024, IMPROVING TO $9.4 MILLION NON-GAAP OPERATING LOSS DECREASED BY 36% COMPARED TO THE FIRST QUARTER OF 2024, IMPROVING TO $5.8 MILLION 14 NEW CLIENTS SIGNED YEAR-TO-DATE, INCLUDING A NATIONAL HEALTH PLAN, REGIONAL PLAN, 12 EMPLOYERS, AND TWO PHARMA COMPANIES STRATEGIC PLATFORM EXPANSION THROUGH GLP-1 PRESCRIBING (MEDIORBIS), BEHAVIORAL HEALTH (RULA), AND CARDIOMETABOLIC SUPPORT VIA A NATIONAL BENEFIT PLAN ADMINISTRATOR GLP-1 SOLUTION EXPANDED WITH VIRTUAL PRESCRIBING AND INTEGRATION INTO CHRONIC CONDITION PROGRAMS ARTIFICIAL INTELLIGENCE (AI) TRANSFORMATION UNDERWAY, AUTOMATING WORKFLOWS, LOWERING COSTS, AND ENHANCED OPERATIONAL SCALABILITY REFINANCED DEBT AND RAISED EQUITY, STRENGTHENING BALANCE SHEET, EXTENDING CASH RUNWAY AND PROVIDING OPERATING FLEXIBILITY TO DRIVE STRATEGIC PLANS DARIO REMAINS ON TRACK TO ACHIEVE OPERATIONAL CASH FLOWBREAKEVEN RUN RATE BY THE END OF 2025 GIVEN EXISTING ACCOUNT EXPANSION, NEW CONTRACT WINS AND A PIPELINE OF NEAR-TERM OPPORTUNITIES DARIO WILL HOST AN INVESTOR CONFERENCE CALL AND WEBCAST AT 8:30 A.M.

DARIOHEALTH REPORTS FIRST QUARTER 2025 FINANCIAL AND OPERATING RESULTS

NEW DATA, PUBLISHED IN JMIR, DEMONSTRATES THE VALUE OF PERSONALIZED MESSAGING ENCOURAGING FLU VACCINATIONS IN DARIO MEMBERS WITH DIABETES NEW YORK , MAY 8, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, ANNOUNCED TODAY NEW RESEARCH PUBLISHED IN THE JOURNAL OF MEDICAL INTERNET RESEARCH ("JMIR") DEMONSTRATING THE EFFECTIVENESS OF PERSONALIZED DIGITAL HEALTH INTERVENTIONS TO DRIVE FLU VACCINE AWARENESS IN DARIO MEMBERS LIVING WITH DIABETES. PEOPLE LIVING WITH DIABETES ARE AT RISK OF SEVERE COMPLICATIONS FROM THE FLU, YET LOW AWARENESS KEEPS MANY FROM RECEIVING AN INFLUENZA VACCINATION.

DARIO'S DIGITAL HEALTH SOLUTION DEMONSTRATES EFFECTIVENESS IN NEW RESEARCH EXAMINING FLU VACCINATION AWARENESS IN HIGH-RISK POPULATIONS

COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:30 A.M. EASTERN TIME NEW YORK , MAY 7, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, ANNOUNCED TODAY THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE 1ST QUARTER ENDED MARCH 31 ST, 2025 AND WILL HOST A CONFERENCE CALL AND WEBCAST AT 8:30 A.M.

DARIOHEALTH TO REPORT FIRST QUARTER 2025 RESULTS ON WEDNESDAY, MAY 14, 2025

$32.5 MILLION FUNDED AT CLOSE; UP TO $17.5 MILLION OF ADDITIONAL CAPITAL AVAILABLE AT THE COMPANY'S OPTION, SUBJECT TO THE ACHIEVEMENT OF CERTAIN REVENUE THRESHOLDS. CAPITAL FROM THE TRANSACTION IS EXPECTED TO SUPPORT EXECUTION OF STRATEGIC PLAN AND FUEL CONTINUED GROWTH.

DARIOHEALTH CLOSES STRATEGIC REFINANCING OF EXISTING DEBT FACILITY OF UP TO $50 MILLION TO PROVIDE ADDITIONAL OPERATIONAL FLEXIBILITY AND SUPPORT GROWTH INITIATIVES

NEW YORK , APRIL 21, 2025 /PRNEWSWIRE/ --DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADING GLOBAL DIGITAL HEALTH COMPANY, TODAY ANNOUNCED THAT ZVI BEN-DAVID , CHIEF FINANCIAL OFFICER, WILL RETIRE FROM HIS ROLE, EFFECTIVE MAY 15, 2025 . THE COMPANY HAS APPOINTED CHEN FRANCO-YEHUDA AS ITS NEW CHIEF FINANCIAL OFFICER,TREASURER, AND SECRETARY,AND WILL ASSUME THE ROLE UPON MR.

DARIOHEALTH ANNOUNCES CFO TRANSITION

STRATEGIC PARTNERSHIP EXPANDS DARIO'S EMPLOYER FOOTPRINT AND HAS ALREADY STARTED CONTRIBUTING TO RECURRING REVENUES IN Q1 OF 2025 NEW YORK , APRIL 17, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED A NEW STRATEGIC PARTNERSHIP WITH A LEADING BENEFIT ADMINISTRATOR TO DELIVER ITS COMPREHENSIVE CARDIOMETABOLIC SOLUTION INCLUDING A GLP-1 SUPPORT PROGRAM AND FULL AI-DRIVEN DIGITAL HEALTH SUITE TO EMPLOYERS, WITH INITIAL CLIENTS ALREADY IMPLEMENTED AND CONTRIBUTING TO REVENUE SINCE JANUARY 2025. THIS MARKS DARIO'S FIRST NATIONAL BENEFIT ADMINISTRATOR PARTNERSHIP AND REPRESENTS A STRATEGIC STEP TOWARD BROADER ADOPTION ACROSS BENEFIT ADMINISTRATION CHANNELS.

DARIOHEALTH COLLABORATES WITH LEADING NATIONAL BENEFIT PLAN ADMINISTRATOR TO OFFER CARDIOMETABOLIC SOLUTION INCLUDING A GLP-1 SUPPORT PROGRAM TO EMPLOYERS

SECOND MAJOR HEALTHCARE EMPLOYER SIGNS WITH DARIOHEALTH, ACCELERATING GROWTH IN 2025 AND REINFORCING ITS LEADERSHIP IN AI-POWERED, CLINICALLY VALIDATED DIGITAL HEALTH SOLUTIONS FOR CHRONIC CONDITION MANAGEMENT NEW YORK , APRIL 8, 2025 /PRNEWSWIRE/ -- DARIOHEALTH CORP. (NASDAQ: DRIO) ("DARIO" OR THE "COMPANY"), A LEADER IN THE GLOBAL DIGITAL HEALTH MARKET, TODAY ANNOUNCED A NEW EMPLOYER PARTNERSHIP WITH ONE OF THE NATION'S MOST RESPECTED RESEARCH AND MEDICAL INSTITUTIONS. THE SIGNED AGREEMENT IS ALREADY LIVE AND GENERATING RECURRING REVENUE IN 2025, MARKING A SIGNIFICANT MILESTONE IN DARIO'S ONGOING EXPANSION AMONG INNOVATION-DRIVEN EMPLOYERS SEEKING MEASURABLE HEALTH OUTCOMES AND ROI.

DarioHealth Corp.

DRIO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DarioHealth Corp.

DRIO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DRIO